The company presented 37 accepted abstracts at ASCO 2026, focused on using AI, genomic data, clinical records, imaging, pathology, and real-world outcomes to improve cancer treatment decisions. That matters because oncology is still full of messy decision points: which therapy to use, which patients are most likely to respond, who should be matched to a trial, and when disease signals are showing up earlier than standard tools can catch.
The investment case is basically this:
* Tempus is not just selling diagnostic tests
* It is building a large multimodal healthcare dataset
* That dataset can feed AI models across treatment selection, clinical trial matching, drug development, and disease monitoring
* The more patient records and outcomes it adds, the more useful the platform could become
* If doctors and pharma companies depend on it, the business could look more like healthcare infrastructure than a testing company
That is why investors are comparing the opportunity to data platforms in other industries. Finance has Bloomberg. Advertising has customer data platforms. Healthcare still has fragmented patient records, disconnected labs, slow trial recruitment, and treatment decisions made with incomplete information.
Tempus is trying to sit in the middle of that.
The doctor-facing value is pretty straightforward:
* Faster identification of relevant mutations
* Better matching between patients and therapies
* Earlier detection or monitoring of disease signals
* Less trial-and-error treatment selection
* More efficient clinical trial matching
The pharma angle may be even more important. Drug developers spend billions trying to get therapies through trials, and many fail because they cannot identify the right patient population or prove a strong enough response signal. If Tempus can help pharma companies design better trials, recruit better patients, or predict responses more accurately, the revenue opportunity goes beyond oncology diagnostics.
The Pelosi connection adds attention.
But the real investment question is bigger:
Can Tempus turn AI-driven healthcare data into a platform doctors and drug developers rely on?
If yes, this story is no longer just about diagnostics.
It becomes a bet on AI becoming core infrastructure for medicine.